Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crenezumab in mild to moderate Alzheimer's disease
NCT02353598Phase 1Completed
- Sponsor
- Genentech
- Start
- Feb 2015
- Primary completion
- Nov 2016
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of crenezumab in Alzheimer's disease (AD) (5 arms), sponsored by Genentech. Primary endpoints: Number of participants with anti-crenezumab antibodies at Week 69, Number of participants with suicidal ideation, suicidal behavior, and self-injurious behavior without suicidal intent at Week 69 and 5 more. Started Feb 2015; status: completed.
02
Drugs
crenezumab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02353598.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02353598.